mobic and Gastritis

122 patients with osteoarthrosis, who have in the past medical history verified chronic gastritis (50 males and 72 females) at the age from 42 to 64 have been examined. Control group was comprised of 40 patients with osteoarthrosis without gastroduodenal zone pathology in the past medical history. For arthralgia relief patients were prescribed meloxicam (average dose--12.5 - 1.39 mg daily) or nimesulide (average dose--150 ± 14.91 mg daily). As a result of this research it was determined that administration of selective NSAID (meloxicam and nimesulide) in patients with chronic gastritis in the past medical history raised the risk of NSAID gastropathy/dyspepsia 2.9 times (P < 0.03) than in patients without associated gastroduodenal zone pathology. Atrophy of gastric mucosa is associated with higher risks (P > 0.05) of erosive gastropathy. Patients with chronic gastritis in the past medical history when taking NSAID with the purpose of gastropathy prevention are recommended to undergo gastroprotective therapy.

Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Chronic Disease; Female; Gastritis; Humans; Male; Meloxicam; Middle Aged; Osteoarthritis; Protective Agents; Sulfonamides; Thiazines; Thiazoles

Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Celecoxib; Cost-Benefit Analysis; Cyclooxygenase Inhibitors; Drug Therapy, Combination; Gastritis; Humans; Lactones; Meloxicam; Netherlands; Pyrazoles; Sulfonamides; Sulfones; Thiazines; Thiazoles